Valuation : Epigenomics AG

Market Cap 789K 917K 743K 678K 1.27M 86.6M 1.27M 8.78M 3.41M 44.43M 3.44M 3.37M 143M P/E 2024
-0.29x
P/E 2025 -2.51x
Enterprise Value 11.76M 13.66M 11.06M 10.1M 18.9M 1.29B 18.95M 131M 50.72M 662M 51.3M 50.18M 2.13B EV / Sales 2024
-
EV / Sales 2025 490x
Free-Float
70.75%
Yield 2024 *
-
Yield 2025 -
1 day+2.78%
1 week+1.65%
Current month+2.78%
1 month+1.65%
3 months+6.32%
6 months-3.65%
Current year+2.78%
1 week 0.9
Extreme 0.9
0.92
1 month 0.9
Extreme 0.9
1.56
Current year 0.84
Extreme 0.84
1.56
1 year 0.84
Extreme 0.84
1.59
3 years 0.5
Extreme 0.5
3.65
5 years 0.5
Extreme 0.5
25.88
10 years 0.5
Extreme 0.5
1,187.36
Manager TitleAgeSince
Investor Relations Contact - -
Corporate Officer/Principal 55 01/02/2024
Director TitleAgeSince
Chairman 58 01/03/2023
Director/Board Member 55 01/06/2020
Director/Board Member 56 05/02/2024
Date Insider Type Main position Quantity % Market Cap. Importance
29/12/22 Buy

Chief Financial Officer

2,000 0.0122%
07/09/21 Sell

Director

7,790 0.0637%
01/02/21 Buy

Chairman

6,355 0.1079%
Change 5-day change 1-year change 3-year change Capi.($)
+2.78%+1.65%+6.32%-69.92% 917K
+1.03%+6.42%+297.74%+42.93% 3.94B
-1.18%-8.17%+88.95%+256.53% 3.92B
-4.79%-6.01%+38.90%+59.29% 3.59B
+2.05%-2.83%+299.69%+422.92% 2.58B
-1.65%-9.61%-27.70%-31.45% 2.14B
-3.43%+21.23%+59.43% - 1.82B
-0.68%-12.54%+210.17%-28.93% 1.1B
+1.11%0.00%+24.61%+44.34% 1.06B
-1.55%-14.45%+8.05%+56.49% 613M
Average +0.31%-2.47%+100.62%+83.58% 2.08B
Weighted average by Cap. -0.28%-1.55%+132.23%+129.92%

Financials

2024 2025
Net sales - 24K 27.89K 22.58K 20.63K 38.59K 2.63M 38.69K 267K 104K 1.35M 105K 102K 4.35M
Net income -3.35M -3.9M -3.15M -2.88M -5.39M -368M -5.4M -37.27M -14.46M -189M -14.63M -14.31M -608M -314K -365K -295K -270K -505K -34.45M -506K -3.49M -1.35M -17.68M -1.37M -1.34M -56.95M
Net Debt 10.46M 12.15M 9.84M 8.99M 16.81M 1.15B 16.86M 116M 45.11M 589M 45.62M 44.63M 1.9B 10.97M 12.74M 10.32M 9.43M 17.63M 1.2B 17.68M 122M 47.31M 617M 47.86M 46.81M 1.99B
Logo Epigenomics AG
Epigenomics AG is a Germany-based molecular diagnostics company focused on blood-based detection, prognosis and monitoring of cancers using deoxyribonucleic acid (DNA) methylation technology. It develops and commercializes blood-based diagnostic products across multiple cancer indications. The Company's main product is Epi proColon, a blood test for colorectal cancer screening. Along with the blood-based tests the Company offers services related to research, product development, regulatory approval and manufacturing of in-vitro diagnostic (IVD) products. It also offers Epi proLung, a blood-based test that detects the presence of lung cancer in blood plasma. The Company is present in Europe and the United States.
Employees
3
Date Price Change Volume
04/09/26 0.9250 +2.78% 0
03/09/26 €0.9000 0.00% 0
02/09/26 €0.9000 -0.55% 0
01/09/26 €0.9050 +0.56% 14
31/08/26 €0.9000 0.00% 449

Annual profits - Rate of surprise